MURANO update: MRD negativity in CLL
The MURANO trial (NCT02005471) compared the benefit of venetoclax plus rituximab vs. bendamustine plus rituximab in chronic lymphocytic leukemia (CLL), for which further results were presented at the ...
Author: VJHemOnc
Added: 06/27/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 27, 2018 Category: Cancer & Oncology Source Type: podcasts
How can we tackle treatment failure in ALL?
Although there have been significant advancements in the treatment of acute lymphoblastic leukemia (ALL) in the last few decade, many patients still fail treatment. In this interview, recorded at the ...
Author: VJHemOnc
Added: 06/27/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 27, 2018 Category: Cancer & Oncology Source Type: podcasts
Novel CLL therapies: the future
The multitude of novel therapies in the field of chronic lymphocytic leukemia (CLL) paves the way for exciting future possibilities. In this interview, Jennifer Woyach, MD, of the Ohio State Universit...
Author: VJHemOnc
Added: 06/27/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 27, 2018 Category: Cancer & Oncology Source Type: podcasts
Promises and challenges in up-and-coming CLL therapies
Promising novel therapies are on the horizon within the field of chronic lymphocytic leukemia (CLL). Here, Jennifer Woyach, MD, of the Ohio State University Comprehensive Cancer Center, Columbus, OH, ...
Author: VJHemOnc
Added: 06/27/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 27, 2018 Category: Cancer & Oncology Source Type: podcasts
Personalized dendritic cell vaccine for acute leukemia and multiple myeloma
In this interview, David Avigan, MD, from Beth Israel Deaconess Medical Centre, Boston, MA, discusses the exciting therapeutic area of personalized vaccines, which aim to produce tumor-specific immuni...
Author: VJHemOnc
Added: 06/27/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 27, 2018 Category: Cancer & Oncology Source Type: podcasts
IDH1 inhibitor ivosidenib for the treatment of relapsed/ refractory AML
A Phase I trial (NCT02074839) investigating the IDH1 inhibitor ivosidenib has demonstrated encouraging results in relapsed/refractory acute myeloid leukemia (AML). In this interview, held at the Ameri...
Author: VJHemOnc
Added: 06/26/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 26, 2018 Category: Cancer & Oncology Source Type: podcasts
Tolerance and alternative kinase inhibitors in CLL
Intolerance is the most common reason for discontinuing PI3K or BTK inhibitor drugs used for the treatment of chronic lymphocytic leukemia (CLL), and it has been found that the intolerant patient popu...
Author: VJHemOnc
Added: 06/26/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 26, 2018 Category: Cancer & Oncology Source Type: podcasts
An unmet need in CLL: patients failing ibrutinib and idelalisib
Relapse and failure of ibrutinib and idelalisib regimens in chronic lymphocytic leukaemia (CLL) is becoming an increasingly common. Here, Christopher Fox, MBChB(Hons), MRCP FRCPath, of Nottingham Univ...
Author: VJHemOnc
Added: 06/26/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 26, 2018 Category: Cancer & Oncology Source Type: podcasts
Identifying TP53 disruptions: a diagnostic measure in CLL
Current diagnostic techniques for chronic lymphocytic leukemia (CLL), which include Sanger sequencing and fluorescent in-situ hybridization, can be complex and costly. Here, Anna Schuh, MD, PhD, MRCP,...
Author: VJHemOnc
Added: 06/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2018 Category: Cancer & Oncology Source Type: podcasts
Discontinuing treatment and predicting relapse in CML
Chronic myeloid leukemia (CML) stem cells are thought to evade treatment through disruption in the environment within the bone marrow, creating a proinflammatory microenvironment in which there is exc...
Author: VJHemOnc
Added: 06/21/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 21, 2018 Category: Cancer & Oncology Source Type: podcasts
Working in Leukemias, Will Enter into Solid Tumors | Molecule TAK-931 is the First Step
Ana Limon Carrera, Takeda Oncology, talks about Working in Leukemias, Will Enter into Solid Tumors | Molecule TAK-931 is the First Step at ASCO 2018
Author: Annual-Meeting
Added: 06/14/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 14, 2018 Category: Cancer & Oncology Source Type: podcasts
Immunotherapy clinical trial participation in R/R AML
Despite recent advancements in CAR T-cell therapy for the treatment of acute myeloid leukemia (AML), standard chemotherapy is still the mainstay of treatment for most AML patients. Here, Marion Subkle...
Author: VJHemOnc
Added: 06/12/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 12, 2018 Category: Cancer & Oncology Source Type: podcasts
MRD: pivotal to progress in AML
Acute myeloid leukemia (AML) is a highly heterogenous disease, and the specific mutations that are present in the patient play a large role in the prognosis. Here, Andrew Wei, MBBS, PhD, FRACP, FRCPA,...
Author: VJHemOnc
Added: 06/11/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 11, 2018 Category: Cancer & Oncology Source Type: podcasts
Understanding gene-gene interactions via machine learning: Pandoras box?
Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, Andrew Wei, MBBS, PhD, FRACP, FRCPA, from Monash University, Melbourne, Austr...
Author: VJHemOnc
Added: 06/11/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 11, 2018 Category: Cancer & Oncology Source Type: podcasts
How can we improve CAR T-cell therapy?
Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, Marion Subklewe, MD, from LMU Hospital Munich, Munich, Germany, gives insight...
Author: VJHemOnc
Added: 06/11/2018 (Source: Oncology Tube)
Source: Oncology Tube - June 11, 2018 Category: Cancer & Oncology Source Type: podcasts
